

Patient Enrollment Form for ROCTAVIAN® (valoctocogene roxaparvovec-rvox)



To learn more about BioMarin RareConnections™ call 1.833.ROCTAVIAN (1.833.762.8284), hours M–F, 8 am–8 pm (ET)

All required fields are purple and bolded First Name Middle Initial Suffix **Last Name** Date of Birth (mm/dd/yyyy) Gender ☐ Male ☐ Female ☐ Other Address Floor/Suite/Unit **ZIP Code** City State **PATIENT** Mobile Phone (same as primary) **Primary Phone Email Preferred Method of Contact** Preferred Language: ☐ English ☐ Spanish ☐ Other language (please specify) ☐ Primary Phone ☐ Mobile Phone ☐ Email Authorized Representative Name (if applicable) Relationship to Patient Email Phone **First Name Last Name** Specialty **NPI Number State License Number Medicaid Number** Tax ID Name of Institution/Practice **PRESCRIBER** Address Floor/Suite/Unit City State ZIP Code Phone Fax Email Preferred Method of Contact ☐ Phone ☐ Fax ☐ Email Primary Contact Name (if different from prescriber) Phone Fax Email Provide copies of all medical and prescription cards — front and back ☐ Patient has no insurance **Primary Medical Insurance Name Insurance Phone** INSURANCE Subscriber Name Relationship to Patient Member ID Plan Code Group Prescription (PBM) Insurance Name Insurance Phone Subscriber Name RxGROUP Member ID RxBIN **RxPCN**

Patient's l	Full Name				Dat	te of birth (mm/dd/yyyy)	
CLINICAL AND LAB RESULTS	ICD Code: D66.0 Hereditary factor VIII deficiency (please specify below) Classic hemophilia Deficiency factor VIII (with functional defect) Hemophilia NOS Hemophilia A Other diagnosis (Please specify) REQUIRED LAB ELIGIBILITY RESULTS DOCUMENTATION Before administration of ROCTAVIAN, the following baseline assessments for AAV5 antibodies and liver health are required and results may be requested by the						
	patient's insurance provider. Please call BioMarin RareConnections at 1.833.762.8284, or your BioMarin representative, if you have questions about these tests including the required companion diagnostic (CDx) Please Confirm Test Status:						
<u> </u>	AAV5 Antibody Test: AAV5 DetectCDx™		☐ Completed			□ Not completed	
CLINICAL AN	Liver Function Test: Alanine transaminase (ALT) Note to prescriber: Blood tests for liver function are included in the liver fibrosis assessment listed below		Completed As part of liver fibrosis assessment blood draw			☐ Not completed	
	Liver Fibrosis Assessment: via blood test (e.g., FibroTest®, FibroSURE® or similar OR via liver elastography ultrasound (e.g., FibroScan®) Note to prescriber: Blood tests for liver fibrosis include liver function (ALT) results and the similar of		Via blood draw	Completed Via ultrasound		☐ Not completed	
	Patient allergies □ NKDA □ Yes (please list) Concurrent medications						
PRESCRIPTION INFUSION SITE	□ Information provided in Prescriber section on first page Infusion Site Name						
	Address	ddress			Floor/Suite/Unit		
	City			State ZIP Code		ZIP Code	
	Infusion Site NPI	Site NPI Infusion Site Contact (if available)					
	Phone	Fax Email					
	Current weight (kg)	Date weight measured (mm/dd/yyyy)					
	ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) is provided in 10 mL vials containing an extractable volume of no less than 8 mL (6 x 10 ¹³ vg). Dose volume is based on body weight. To calculate a patient's dose in milliliters (mL), multiply body weight in kg by 3. The multiplication factor 3 represents the per-kilogram dose (6 x 10 ¹³ vg/kg) divided by the amount of vector genomes per mL of the ROCTAVIAN solution (2 x 10 ¹³ vg/mL). To calculate number of vials to be thawed, divide patient's dose volume in mL by 8 and round up to the next whole number of vials.						
	Patient's weight (kg) Dose (mL) number of vials required						
		ml as a single intravenous infusion per m	anufacturer product labeling				
	Dose:vg Dispense (number of vials): N				NDC #: 68135-927-48		
PRODUCT COORDINATION	☐ Ship-to-site for product (if different from infusion site) ☐ (select if same as infusion site)						
	Ship-to-site Name						
	Address			F	loor/Suit	e/Unit	
	City			S	State	ZIP Code	
	Ship-to-site Contact Name		Phone	F	ax		
	Email	Shipping Instruction	ins				
	Proceribor Declaration: Ducianing bala	w, I, as the prescribing physician, certify	that the information provided -	n this form	ae compl-	atad by ma or at my direction	
PRESCRIBER DECLARATION	I understand and agree that, as the Prescriber, I will comply with my state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the Prescriber. I verify that the patient and prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed ROCTAVIAN based on my professional judgment of medical necessity. I have informed my patient of the resources available in the BioMarin RareConnections program and have confirmed my patient's (or their respective caregiver's) consent to enroll in the program. I have obtained all required patient permissions and have complied with all federal and state laws with respect to disclosures and release of the provided information to BioMarin Pharmaceutical Inc., BioMarin RareConnections, and its affiliates, agents, and contractors (collectively, "BioMarin", as well as to or between other service providers such as laboratories and pharmacies, and for the purposes described herein by any means allowed under applicable law. I understand that the information provided herein by any means allowed under applicable law. I understand that the information provided herein will be used for the purposes of BioMarin to investigate and verify patient's insurance and coverage benefits, to contact this patient to help obtain a signed patient consent form and/or to refer the patient to or contact the patient for purposes of enrollment in a patient education program, verify patient's insurance coverage benefits for ROCTAVIAN and any related services, to coordinate the dispensing and delivery of ROCTAVIAN (including transmitting the prescription to the appropriate pharmacies) utilizing the patient's benefit plan, assist in initiating or continuing therapy, provide prior authorization and appeals information, verify eligibility for a co-pay program, and identify additional financial resource						
	support associated with ROCTAVIAN, a			control, dat	a analysis	s, and gathering feedback to	
	support associated with ROCTAVIAN, a	nd for BioMarin internal business purpo ake a selection			,		